Prediction trend of the status quo of number theory -- release of 2019 China Biomedical Industry Development Report

On December 28, 2019, under the guidance of China Pharmaceutical Materials Association, the "2019 China Pharmaceutical new wisdom forum" jointly sponsored by Sina pharmaceutical and China Pharmaceutical Materials Association think tank for food and drug industry was successfully held in Beijing At the meeting, Sina pharmaceutical and CCID consultants jointly released the 2019 China biomedical industry development report (hereinafter referred to as the report) to deeply analyze the development pattern of China's biomedical industry under the new situation With the steady development of China's social economy, the further improvement of national health awareness and consumption level, and the continuous improvement of technological innovation level, the "three medical" linkage reform continues to enter the deep-water area, and the biomedical industry with drugs and medical devices as the main body has become the forefront focus of a new round of industrial competition Focusing on hot events, market scale, R & D innovation, investment and financing data, through specific events and detailed data, the report profoundly describes the development process of China's biomedical industry in 2019, and forecasts the industrial development trend, providing strong support and reference for industrial decision makers In 2019, the biomedical industry entered a new stage of development New breakthroughs have been made in global cancer vaccine, heart printing and other technologies Technological innovation has become the driving force for the development of the industry Frequent M & A and IPO events have occurred, and the capital market is still hot A number of China's pharmaceutical and medical insurance policies have been issued to promote the industry to speed up the reshuffle, new drugs to speed up the listing, and the industry has a rapid development momentum The report takes the time axis as the order to check the international and domestic hot events in 2019 In the context of promoting the work of consistency evaluation and medical insurance negotiation, the report cites a large number of data and events in the aspects of market data, drug declaration, clinical trials, consistency evaluation and investment and financing, and comprehensively interprets the development status of China's biomedical industry from the perspective of quantity change, structure change and ranking In terms of market, the scale of global biomedical market is rising steadily, and it is expected to reach US $1.7 trillion in 2019 The scale of China's biomedical market is rising rapidly, which is expected to reach 2.5 trillion yuan in 2019, with an annual growth rate of more than 10% It has surpassed the global market and become the main driving force for global market growth At the same time, the market structure continued to differentiate, and the market share of medical devices gradually expanded, which is expected to reach 25% in 2019 In terms of drug declaration, the number of applications for acceptance has increased steadily, and by November 2019, the total number of applications for acceptance has exceeded 7600 The enthusiasm for R & D continues to rise, and the achievements of R & D and innovation have begun to show, among which the proportion of biological product application and acceptance is rising By November 2019, the proportion of biological product application has exceeded 14%, the highest level since 2015 In terms of clinical trials, the number of effective registration of clinical trials in China has grown rapidly, and by November 2019, it has exceeded 2200 cases Among them, the proportion of phase I and phase II Registration increased to 53.3%, which means more drugs will go to clinical; the proportion of clinical trials of biological drugs increased to 30.6%, which proves that the research and development of biological drugs is getting better In terms of consistency evaluation, affected by policies, the number of declaration and acceptance reached a peak Among them, the number of application acceptance numbers of varieties is top 3: Amoxicillin Capsules (45), amlodipine besylate tablets (42), metformin hydrochloride tablets (38); the number of application acceptance numbers of varieties, amlodipine besylate tablets ranks first, there are 13, cefuroxime ester tablets, rosuvastatin calcium tablets, metformin hydrochloride tablets, metformin hydrochloride sustained-release tablets and montmorillonite powder Next, there are 11 In terms of patent application, the number of patent applications has declined year by year, the competition for pharmaceutical innovation is fierce, the attention of biopharmaceuticals has continued to increase, and the high-level innovation has been strengthened In terms of investment and financing, as of November 2019, 253 investment and financing events have occurred, which is the lowest level in the past five years The total financing amount has reached about 21.7 billion yuan, and the average single financing amount tends to be stable Medicine is the field with the largest number of investment and financing events (141 events) and the largest amount (about 18.2 billion yuan) in the field of medicine and health, with relatively active performance As a whole, the development quality and market capacity of China's biomedical industry have been steadily improved, and the focus of R & D and capital market has gradually shifted to medical devices and biomedical fields Based on the current situation, looking forward to the future The report studies and judges six development trends from the perspectives of new drug declaration, innovation mode, R & D and production, new drug listing, capital investment and enterprise strategy 1 Will turn from; 2 Will turn from; 3 Will turn from; 4 Will turn from; 5 Will turn from; 6 It will turn from.